Full Papers
Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia
Y. Zou1, Y. Fei2, H. Gao3, L.-F. Xie4, Y.-C. Zhong5, Q.-Z. Yang6, D.-L. Wang7, X.-W. Zhang8
- Department of Rheumatology and Immunology, Peking University International Hospital, and Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
- Department of Rheumatology and Immunology, Peking University People’s Hospital, and Department of Rheumatology and Immunology, Beijing Haidian Hospital (Beijing Haidian Section of Peking University Third Hospital), Beijing, China.
- Department of Rheumatology and Immunology, Peking University International Hospital, and Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
- Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
- Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.
- Department of Ultrasound, Peking University People’s Hospital, Beijing, China.
- Department of Orthopaedics, The Hospital of Renmin University of China, Beijing, China.
- Department of Rheumatology and Immunology, Peking University International Hospital, and Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China. xuewulore@163.com
CER12545
2020 Vol.38, N°5
PI 0896, PF 0902
Full Papers
PMID: 31858958 [PubMed]
Received: 29/06/2019
Accepted : 01/10/2019
In Press: 19/12/2019
Published: 02/10/2020
Abstract
OBJECTIVES:
To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness.
METHODS:
One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into five groups according to MU manifestations. Circulating Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured. Thirty patients from the gout group and 10 from the hyperuricaemia group, were treated for 1 year with urate-lowering therapy (ULT).
RESULTS:
Patients with gout and tophus and/or bone erosion had the highest DKK-1 and RANKL levels. Patients with gout and MU-evidenced aggregates and/or double-contour signs had higher DKK-1 and RANKL levels than the normal MU group (p<0.001). Patients with hyperuricaemia and abnormal MU findings had significantly higher DKK-1 and RANKL levels than those with normal MU findings. DKK-1 and RANKL levels positively correlated with disease duration in patients with gout (r=0.430, p<0.001; r=0.359, p<0.001, respectively) and hyperuricaemia (r=0.446, p<0.001; r=0.379, p<0.001, respectively). After ULT, MU abnormalities disappeared in 12 and 8 patients with gout and hyperuricaemia, respectively. The largest tophus diameter decreased in patients with gout (t=6.092, p<0.001). DKK-1 and RANKL concentrations significantly decreased in all patients. Lower serum urate levels corresponded with higher ratios of normal MU features in all patients.
CONCLUSIONS:
In patients with gout and hyperuricaemia, MU manifestations were associated with DKK-1 and RANKL levels and were ameliorated after ULT. Thus, MU could be a useful tool in assessing bone remodelling and monitoring disease responsiveness.
